Bristol-Myers Squibb Company

65.71+0.2500+0.38%Vol 6.96M1Y Perf 8.19%
Apr 19th, 2021 14:34 DELAYED
BID65.70 ASK65.71
Open65.42 Previous Close65.46
Pre-Market65.10 After-Market-
 -0.36 -0.55%  - -
Target Price
74.30 
Analyst Rating
Moderate Buy 1.77
Potential %
13.54 
Finscreener Ranking
★★+     48.87
Insiders Trans % 3/6/12 mo.
-100/-100/-76 
Value Ranking
★★+     49.45
Insiders Value % 3/6/12 mo.
-100/-100/-92 
Growth Ranking
★+     41.80
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-91 
Income Ranking
★★★★+     60.42
Market Cap146.79B 
Earnings Rating
Buy
Price Range Ratio 52W %
88.92 
Earnings Date
29th Apr 2021

Today's Price Range

65.2165.92

52W Range

54.0767.16

5 Year PE Ratio Range

14.10116.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.55%
1 Month
5.28%
3 Months
-1.62%
6 Months
6.89%
1 Year
8.19%
3 Years
24.97%
5 Years
-3.30%
10 Years
166.52%

TickerPriceChg.Chg.%
BMY65.710.25000.38
AAPL134.620.46000.34
GOOG2 303.856.09000.27
MSFT258.93-1.8100-0.69
XOM56.21-0.4500-0.79
WFC44.310.47001.07
JNJ162.550.31000.19
FB302.38-3.8000-1.24
GE13.400.01000.07
JPM153.22-0.0800-0.05
Financial StrengthValueIndustryS&P 500US Markets
1.30
1.60
0.57
1.37
-3.80
Leverage Ratio 2.80
ProfitabilityValueIndustryS&P 500US Markets
71.90
-12.80
11.60
1.20
-26.65
RevenueValueIndustryS&P 500US Markets
31.74B
14.21
25.33
17.30
DividendsValueIndustryS&P 500US Markets
3.13
1.96
12.48
9.78
Payout ratio273.00
Earnings HistoryEstimateReportedSurprise %
Q04 20201.371.466.57
Q03 20201.491.639.40
Q02 20201.461.6311.64
Q01 20201.481.7216.22
Q04 20190.881.2238.64
Q03 20191.061.1710.38
Q02 20191.061.1811.32
Q01 20191.091.100.92
Earnings Per EndEstimateRevision %Trend
3/2021 QR1.821.68Positive
6/2021 QR1.906.15Positive
12/2021 FY7.451.78Positive
12/2022 FY8.063.33Positive
Next Report Date29th Apr 2021
Estimated EPS Next Report1.82
Estimates Count5
EPS Growth Next 5 Years %7.00
Volume Overview
Volume6.96M
Shares Outstanding2.23B
Trades Count54.76K
Dollar Volume1.33B
Avg. Volume12.40M
Avg. Weekly Volume9.60M
Avg. Monthly Volume10.72M
Avg. Quarterly Volume12.40M

Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 65.46 per share at the end of the most recent trading day (a 1.58% change compared to the prior day closing price) with a volume of 14.59M shares and market capitalization of 146.79B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.

The one-year performance of Bristol-Myers Squibb Company stock is 8.19%, while year-to-date (YTD) performance is 5.53%. BMY stock has a five-year performance of -3.3%. Its 52-week range is between 54.07 and 67.16, which gives BMY stock a 52-week price range ratio of 88.92%

Bristol-Myers Squibb Company currently has a PE ratio of -15.50, a price-to-book (PB) ratio of 3.66, a price-to-sale (PS) ratio of 4.41, a price to cashflow ratio of 9.90, a PEG ratio of 2.32, a ROA of -6.94%, a ROC of 1.35% and a ROE of -19.18%. The company’s profit margin is -26.65%, its EBITDA margin is 11.60%, and its revenue ttm is $31.74 Billion , which makes it $14.21 revenue per share.

Of the last four earnings reports from Bristol-Myers Squibb Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.82 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (1.77), with a target price of $74.3, which is +13.54% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bristol-Myers Squibb Company has a dividend yield of 3.13% with a dividend per share of $1.96 and a payout ratio of 273.00%.

Bristol-Myers Squibb Company has a Buy technical analysis rating based on Technical Indicators (ADX : 4.96, ATR14 : 1.41, CCI20 : 225.19, Chaikin Money Flow : 0.17, MACD : 0.62, Money Flow Index : 54.06, ROC : 3.40, RSI : 62.71, STOCH (14,3) : 95.45, STOCH RSI : 1.00, UO : 65.46, Williams %R : -4.55), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Dubow (Option Excercise at a value of $0), Adam Dubow (Sold 4 100 shares of value $252 283 ), Christopher S. Boerner (Option Excercise at a value of $0), David V. Elkins (Option Excercise at a value of $0), Dinesh C. Paliwal (Buy at a value of $999 966), Elizabeth A. Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 64 840 shares of value $4 052 968 ), Joseph Eid (Option Excercise at a value of $0), Joseph Eid (Sold 5 327 shares of value $340 928 ), Julia A. Haller (Option Excercise at a value of $0), Karen Murphy Santiago (Option Excercise at a value of $0), Louis S. Schmukler (Option Excercise at a value of $0), Louis S. Schmukler (Sold 25 000 shares of value $1 567 000 ), Michael W. Bonney (Option Excercise at a value of $0), Nadim Ahmed (Option Excercise at a value of $0), Paul von Autenried (Option Excercise at a value of $0), Paul von Autenried (Sold 20 003 shares of value $1 255 191 ), Powell Ann Judge (Option Excercise at a value of $0), Rupert Vessey (Option Excercise at a value of $4 360 456), Rupert Vessey (Sold 142 024 shares of value $8 707 026 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sandra Leung (Sold 141 420 shares of value $8 943 401 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (61.54 %)
8 (61.54 %)
7 (58.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (38.46 %)
5 (38.46 %)
5 (41.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.77
Moderate Buy
1.77
Moderate Buy
1.83

Bristol-Myers Squibb Company

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

CEO: Giovanni Caforio

Telephone: +1 212 546-4000

Address: 430 E. 29th Street, New York 10016, NY, US

Number of employees: 30 250

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

52%48%

Bearish Bullish

55%45%

News

Stocktwits